TABLE 2.

Antimicrobial management of patients enrolled in the retrospective cohort study of hospitalized patients with invasive Salmonella serotype Typhi infection, FoodNet sites, 1999 to 2002a

CharacteristicAll patientsPatients infected with Salmonella serotype Typhi isolates with DCSPatients infected with Salmonella serotype Typhi isolates without DCSP value
Antimicrobial use prior to hospitalization (no. of patients/total no. [%])
    Took any antimicrobial prior to hospitalization31/67 (46)12/24 (50)19/43 (44)NSb
    Took fluoroquinolone prior to hospitalization9/67 (13)4/24 (17)5/43 (12)NS
Antimicrobial use during hospitalization (no. of patients/total no. [%])
    Took any antimicrobial during hospitalization71/71 (100)24/24 (100)47/47 (100)NS
    Took fluoroquinolone during hospitalization32/71 (45)14/24 (58)18/47 (39)NS
    First took fluoroquinolone during hospitalization22/58 (38)11/20 (55)11/38 (29)NS
Aggregate antimicrobial use (prior to and during hospitalization)
    Median (range) no. of days of antimicrobial use prior to hospital discharge6 (2-31)8 (2-31)6 (2-16)0.017
    Median (range) no. of days of fluoroquinolone use prior to hospital discharge0 (0-31)5 (0-31)0 (0-11)0.023
    Median (range) no. of days of fluoroquinolone use prior to hospital discharge among patients treated with fluoroquinolones5 (0-31)8 (0-31)5 (0-11)0.011
    Use of any fluoroquinolone (no. of patients/total no. [%])35/71 (49)15/24 (63)20/47 (43)NS
    Exclusive fluoroquinolone use (no. of patients/total no. [%])4/68 (6)1/24 (4)3/44 (7)NS
    Use of any cephalosporin (no. of patients/total no. [%])61/71 (86)21/24 (88)40/47 (85)NS
Median (range) no. of antimicrobial classes usedc2 (1-4)2 (1-4)2 (1-4)NS
  • a The cohort consisted of 71 patients.

  • b NS, not significant.

  • c Number of classes of antimicrobial agents used to treat typhoid fever, including penicillins, cephalosporins, sulfa drugs, fluoroquinolones, aminoglycosides, macrolides, and carbepenems.